There is a plausible story in which national coverage costs money. A seller licensed everywhere carries more regulatory overhead, more prescriber relationships and more complexity than one operating in a single state, and might reasonably charge for it. There is an equally plausible story running the other way, in which scale lowers unit costs. Neither story is visible in the data — which puts it alongside the other plausible price driver this site has failed to find, in what a flat rate costs.
What the grouping shows
sellers that publishes no list sit at a median of $179 across 244 rows; sellers that fewer than 40 states sit at a median of $170 across 53 rows; sellers that 40 to 49 states sit at a median of $192.50 across 27 rows; sellers that 50 or more sit at a median of $175 across 108 rows. The interquartile ranges overlap each other substantially, and the medians do not run in any order.
Why a null result is worth publishing
Because it removes a variable. A reader comparing two sellers can stop wondering whether the one serving fifty states is charging for the privilege, or whether the one serving three is cheap for a reason. On this roster neither is true, and the price difference between any two sellers has to be explained by something else.
That something else is usually what is bundled into the figure and what sits outside it, which is the subject of the gap between what is shown and what is billed, and what the price does as the dose climbs, which is what a flat rate costs.
What still matters about coverage
Everything, just not the price. A seller that cannot ship to your address is not an option at any figure, and the first question is whether it says where it operates at all. That disclosure question is separate from this pricing one and it has a real answer, unlike this page’s. The arithmetic behind every figure quoted here is in what a GLP-1 actually costs.